Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor versus placebo in primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid
2024-512232-30-00Phase 3Authorised
- Sponsor
- Ipsen
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Elafibranor with Placebo (2 arms). Primary endpoint: Biochemical response at week 52. Planned start Jan 2021; status: authorised.
02
Drugs
elafibranor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2024-512232-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512232-30-00.